Sharess of Eli Lilly are moving higher on Tuesday after the company revealed that a recent study, conducted by the company, showed that its weight-loss drug tirzepatide, the active ingredient in its weight-loss drug Zepbound and diabetes drug Mounjaro, cuts diabetes risk by 94%.
Um, you know, every time we seem to get a, a data set out of either Lily or Novo on with respect to their, their G LP ones, um, it usually surprises to the upside and, and that's what we saw this morning.I mean, a 94% decline in type two almost makes me feel like everyone should be on the drug irrespective of whether they're obese or not.They're testing it in I BS.Um, I mean, you know, we've talked to, to, um, folks who cover the industry before about this.
10 years down the road, five years down the road, et cetera and not knowing that means that your cost savings might be captured and may not be. Do you think that is sort of how the trajectory of this continues, or do you think we'll see a lot of other drug makers that will successfully get into this space and the diabetes related companies will adapt?Yeah, that's a, you know, one of the most um relevant questions we get honestly is kind of like how does the rest of the industry navigate around the success of the obesity drugs?
Um I think what's gonna happen longer term is that once the market does accelerate into that sort of general vicinity, you are gonna see price decreases, you are gonna see more competition.
대한민국 최근 뉴스, 대한민국 헤드 라인
Similar News:다른 뉴스 소스에서 수집한 이와 유사한 뉴스 기사를 읽을 수도 있습니다.
출처: YahooFinanceCA - 🏆 47. / 63 더 많은 것을 읽으십시오 »
출처: YahooFinanceCA - 🏆 47. / 63 더 많은 것을 읽으십시오 »
출처: YahooFinanceCA - 🏆 47. / 63 더 많은 것을 읽으십시오 »